Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1130982 | 0.82 | PREP (0.44) | PREPCYP3A4TNKSCCNE1CDK2 | |
| SCHEMBL6010185 | 0.79 | IDO1 (0.41) | PREPCYP3A4TNKSRBP4IDO1 | |
| SCHEMBL12234460 | 0.77 | — | — | |
| SCHEMBL890196 | 0.77 | — | — | |
| SCHEMBL301936 | 0.77 | — | — | |
| SCHEMBL25136561 | 0.76 | IDO1 (0.33) | PREPCYP17A1CYP3A4IDO1 | |
| SCHEMBL1751342 | 0.76 | MAPK1 (0.49) | PREPALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL10897204 | 0.75 | PREP (0.45) | PREPTNKSTRPA1 | |
| SCHEMBL10750976 | 0.75 | PREP (0.40) | PREPTNKSCCNE1CDK2RBP4 | |
| SCHEMBL10824813 | 0.75 | RAB9A (0.54) | CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4183783-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-24 | — | — | EP | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100119510-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| US-7531535-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080090807-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | PREP 846/4885CYP17A1 4756/4885CYP3A4 1232/4885 |
| US-20100119510-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | PREP 18/4885CYP17A1 604/4885CYP3A4 453/4885 |
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | PREP 2228/4885CYP17A1 1949/4885CYP3A4 2437/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | PREP 3532/4885CYP17A1 2701/4885CYP3A4 2070/4885 |
| US-20080090807-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | PLAT, TFPI, SPINT2 | PREP 49/4885CYP17A1 1234/4885CYP3A4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.